Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: Literature evaluation based on the metabolism and transport drug interaction database

Chemical Research in Toxicology

Volumn 22, Issue 2, 2009, Pages 294-298

  Isoherranen, Nina ^a   Hachad, Houda ^a   Yeung, Catherine K ^a   Levy, Rene H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPRAZOLAM; AMFEBUTAMONE; AMIODARONE; AMITRIPTYLINE; AMODIAQUINE; APREPITANT; ARMODAFINIL; ATAZANAVIR; ATOMOXETINE; ATORVASTATIN; BENZBROMARONE; CAPECITABINE; CARBAMAZEPINE; CELECOXIB; CHLOROQUINE; CHLORPROMAZINE; CILOSTAZOL; CLOMETHIAZOLE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; DATA BASE; DRUG INHIBITION; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSPORT; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; MEDLINE; PLASMA; QUALITATIVE ANALYSIS;

AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; DRUG INTERACTIONS; ENZYME INHIBITORS; PHARMACEUTICAL PREPARATIONS;

EID: 62249151758     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx800491e     Document Type: Article

References (13)

1. U.S. Food and Drug Administration (2008) Guidance for Industry. Safety Testing of Drug Metabolites, FDA, Rockville, MD.
2. U.S. Food and Drug Administration (2006) Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. Draft Guidance, FDA, Rockville, MD.
3. Smith, D. A., and Obach, R. S. (2006) Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579.
4. Brown, H. S., Galetin, A., Hallifax, D., and Houston, J. B. (2006) Prediction of in vivo drug-drug interactions from in vitro data: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin. Pharmacokinet. 45, 1035-1050.
5. Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., and Tremaine, L. M. (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 316, 336-348.
6. Rostami-Hodjegan, A., and Tucker, G. (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interaction. Drug Discovery Today: Technol. 1, 441-448.
7. Kalgutkar, A. S., Obach, R. S., and Maurer, T. S. (2007) Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 8, 407-447.
8. Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., and Parkinson, A. (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions. Drug Metab. Dispos. 34, 191-197.
9. Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L., and Thummel, K. E. (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 32, 1121-1131.
10. Stevens, J. C., and Wrighton, S. A. (1993) Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J. Pharmacol. Exp. Ther. 266, 964-971.
11. Templeton, I. E., Thummel, K. E., Kharasch, E. D., Kunze, K. L., Hoffer, C., Nelson, W. L., and Isoherranen, N. (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin. Pharmacol. Ther. 83, 77-85.
12. Sauer, J. M., Long, A. J., Ring, B., Gillespie, J. S., Sanburn, N. P., DeSante, K. A., Petullo, D., VandenBranden, M. R., Jensen, C. B., Wrighton, S. A., Smith, B. P., Read, H. A., and Witcher, J. W. (2004) Atomoxetine hydrochloride: Clinical drug-drug interaction prediction and outcome. J. Pharmacol. Exp. Ther. 308, 410-418.
13. Preskorn, S. H., Alderman, J., Chung, M., Harrison, W., Messig, M., and Harris, S. (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J. Clin. Psychopharmacol. 14, 90-98.